JFL Life Sciences Ltd (JFLLIFE) — shareholding pattern, promoter holding, financials and share price
About JFL Life Sciences Ltd (JFLLIFE)
JFL Life Sciences Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as JFLLIFE and on the BSE under scrip code 535469. Its ISIN is INE0LA901015.
Incorporated in 2010, JFL Life Sciences Ltd produces and markets a wide range of formulations [1]
JFL Life Sciences Limited, established in 2010, specializes in the manufacturing and marketing of pharmaceutical products, including dry powder injections and various tablets and capsules.
The company has a wide reach with its products distributed across India and exported to 10 countries, including parts of Africa, the Middle East, and CIS nations.
Listed peers in Pharmaceuticals: Lasa Supergenerics Ltd, Roopa Industries Ltd, Parmax Pharma Ltd, Medi Caps Ltd, Walpar Nutritions Ltd, Welcure Drugs & Pharmaceuticals Ltd.
Valuation & Returns
10 Jul 2026At ₹10.6 a share on 10 Jul 2026, JFL Life Sciences Ltd (JFLLIFE) was valued at a price-to-earnings ratio of 5.47x against an industry P/E of 36.41x and a price-to-book of 0.89x on a book value of ₹11.96 per share as of Mar 2025. Solomo computes return on equity of 16.22% and return on capital employed of 21.38% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 5.47x
- Industry P/E
- 36.41x
- P/B
- 0.89x
- EPS (TTM)
- ₹1.94
- Book value / share
- ₹11.96
- ROE
- 16.22%
- ROCE
- 21.38%
- ROA
- 8.9%
- Debt / equity
- 0.27x
- Dividend yield
- 0%
- EBITDA margin
- 8.97%
- 52-week range
- ₹8.55 – ₹15.27
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, JFL Life Sciences Ltd (JFLLIFE) reported revenue of ₹131 crore, net profit of ₹6 crore and earnings per share of ₹0.97. That compares with revenue of ₹82 crore and net profit of ₹4 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹63.05 crore and net profit ₹1.66 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 34 | 43 | 47 | 82 | 131 |
| Net profit (₹ cr) | 3 | 3 | 3 | 4 | 6 |
| EPS (₹) | 0.59 | 0.43 | 0.5 | 0.63 | 0.97 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 22.15% | 34.67% | 76.24% |
| Profit growth | 63.09% | 13.96% | 25.68% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 67.47% of JFL Life Sciences Ltd (JFLLIFE) (unchanged from the previous quarter). Market capitalisation was ₹35 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2022.
Largest disclosed public shareholders in Jun 2026: PRATIK RAJENDRABHAI GANDHI 1.22%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 67.47% | - | - | - | - |
| Mar 2026 | 67.47% | - | - | - | - |
| Dec 2025 | 67.47% | - | - | - | - |
| Sep 2025 | 67.47% | - | - | - | - |
| Jun 2025 | 67.47% | - | - | - | - |
| Mar 2025 | 67.47% | - | - | - | - |
| Sep 2024 | 67.47% | - | - | - | - |
| Mar 2024 | 67.47% | - | - | - | - |